Abstract
Human CSF cyclic AMP and cyclic GMP have been measured as possible indicators of activity of central neurotransmitter-sensitive adenylate or guanylate cyclase. In an attempt to help to identify the specific neurotransmitter systems of origin of human CSF cyclic AMP and GMP, we studied Parkinson patients with and without l-dopa therapy and schizophrenic patients before and after propranolol therapy. No effect of l-dopa or propranolol was found on CSF cyclic nucleotides. However, Parkinson patients had a 40–50% reduction of CSF cyclic AMP and a 80–90% reduction of CSF cyclic GMP compared with the schizophrenic patients. Implications of this finding are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Belmaker, R. H., Ebstein, R. P., Dasberg, H., Levy, A., Sedvall, G., van Praag, H. M.: The effect of propranolol treatment in schizophrenia on CSF amine metabolites and prolactin. (In press, 1978)
Biederman, J., Rimon, R., Ebstein, R. P., Belmaker, R. H., Davidson, J. T.: Cyclic AMP in the CSF of patients with schizophrenia. Br. J. Psychiatry 130, 64–67 (1977)
Biederman, J., Rimon, R., Ebstein, R. P., Zohar, J., Belmaker, R. H.: Neuroleptics reduce spinal fluid cyclic AMP in schizophrenic patients. Neuropsychobiology 2, 324–327 (1976)
Bowers, M. B.: Central dopamine turnover in schizophrenic syndromes. Arch. Gen. Psychiatry 31, 50–54 (1974)
Chase, T. N., Ng, L. K. Y.: Central monoamine metabolism in Parkinson's disease. Arch. Neurol. 27, 486–491 (1972)
Cramer, H., Ng, L. K. Y., Chase, T. N.: Adenosine 3′, 5′-monophosphate in cerebrospinal fluid. Arch. Neurol. 29, 197–199 (1973)
Ebstein, R. P., Biederman, J., Rimon, R., Zohar, J., Belmaker, R. H.: Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment. Psychopharmacology 51, 71–74 (1976)
Hornykiewicz, O.: Dopamine and brain function. Pharmacol. Rev. 18, 925–964 (1966)
Kebabian, J. W., Petzold, G., Greengard, P.: Dopamine-sensitive adenylate cyclase in caudate nucleus of the rat brain and its similarity to the dopamine receptor. Proc. Nat. Acad. Sci. U.S.A. 69, 2145–2149 (1972)
Kiessling, M., Lindl, T., Cramer, H.: Cyclic adenosine monophosphate in cerebrospinal fluid: effects of theophylline, l-dopa and a dopamine receptor stimulant in rats. Arch. Psychiatr. Nervenkr. 220, 325–333 (1975)
Korf, J., Boer, P. H., Fekkes, D.: Release of cerebral cyclic AMP into push-pull perfusates in freely moving rats. Brain Res. 113, 551–561 (1976)
Kuo, J. F., Lee, T. P., Reyes, P. L., Walton, K. G., Donnelly, T. E., Jr., Greengard, P.: Cyclic nucleotide-dependent protein kinase. X. An assay method for the measurement of guanosine 3′, 5′-monophosphate in various biological materials and a study of agents regulating its levels in heart and brain. J. Biol. Chem. 247, 16–22 (1972)
Lloyd, K. G., Mohler, H., Heitz, P., Bartholini, G.: Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and Parkinson patients. J. Neurochem. 25, 789–795 (1975)
McGeer, P. L., McGeer, E. G.: Enzymes associated with the metabolism of catecholamines, acetylcholine and GABA in human controls and patients with Parkinson's disease and Huntington's chorea. J. Neurochem. 26, 65–76 (1976)
Post, R. M., Goodwin, F. K.: Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients. Science 190, 488–489 (1975)
Sebens, J. B., Korf, J.: Cyclic AMP in cerebrospinal fluid: accumulation following probenecid and biogenic amines. Exp. Neurol. 46, 336–344 (1975)
Siggins, G. R., Oliver, A. P., Hoffer, B. J., Bloom, F. E.: Cyclic adenosine monophosphate and norepinephrine: Effects on transmembrane properties of cerebellar Purkinje cells. Science 171, 192 (1971)
Tsang, D., Lal, S., Sourkes, T. L., Ford, R. M., Aronoff, A.: Studies on cyclic AMP in different compartments of cerebrospinal fluid. J. Neurol. Neurosurg. Psychiatry 39, 1186–1190 (1976)
Vapaatalo H., Myllyla, V., Heikkinen, E., Hokkanen, E.: Cyclic AMP in CSF of patients with neurologic disease. N. Engl. J. Med. 296, 691–692 (1976)
Yorkston, N. J., Zaki, S. A., Malik, M. K. U., Morrison, R. C., Havard, C. W. H.: Propranolol in the control of schizophrenic symptoms. Br. Med. J. 4, 633–635 (1974)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Belmaker, R.H., Ebstein, R.P., Biederman, J. et al. The effect of l-dopa and propranolol on human CSF cyclic nucleotides. Psychopharmacology 58, 307–310 (1978). https://doi.org/10.1007/BF00427396
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00427396